Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
about
The mTOR signalling pathway in human cancerTherapeutic Implications of Targeting AKT Signaling in MelanomaConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisCurrent and future trials of targeted therapies in cutaneous melanomaNUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.Interface of signal transduction inhibition and immunotherapy in melanoma.Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.Melanoma genetics and the development of rational therapeutics.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Understanding the biology of melanoma and therapeutic implicationsAbrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasisSelenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk.Patterns of neural differentiation in melanomas.Targeted therapy for melanoma: a primer.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionNovel targeted therapies for the treatment of metastatic melanoma.New horizons in melanoma treatment: targeting molecular pathways.Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldMelanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma.PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.Genetics of melanomaInnovative therapeutic strategies in the treatment of brain metastases.PTEN/MMAC1 expression in melanoma resection specimens.p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumorsGenetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.Issues affecting molecular staging in the management of patients with melanomaUnderstanding signaling cascades in melanomaThe Critical Role of PPARgamma in Human Malignant MelanomaMalignant melanoma in the 21st century: the emerging molecular landscape.The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
P2860
Q54835354-58B68AE2-5EA9-4AA5-B103-03FDF30D959FQ54896249-438E38A9-A303-4452-B6E4-45E98195706EQ54896251-01CAFA79-F164-457D-A462-DBF69277E4F2Q54898478-E6860480-152F-4C00-8BCF-F2EABC714D7CQ54899264-26851E66-EA0F-4DC8-8D70-08BDC5E089FDQ54905064-ABF7C703-B6F1-4352-8DA6-6419B476E3E6Q54905141-A1F116E2-DED9-468C-B32A-814BABC48F69Q54905451-385D4A41-EBCA-464E-8BDD-0F29238FA812Q54905452-C34DA804-77EF-4114-A3D4-47A75E897C78Q54905453-60DBACAA-2D5B-4878-8FAB-6E8A684FD7A1Q54905454-971A81A9-FAF0-4253-BFEC-199AA9AB4FF3Q54905457-8FE7AB4D-64D4-4D80-99AD-2B216448737DQ54905459-3F355C92-25A7-4037-B20A-E5B0616988E5Q54905838-536399E1-C080-48DF-AB4C-494A716F8CE7Q54906023-61C0F74C-9E0A-4DDB-B923-A3E306D16B05Q54906134-15D6B660-2A93-472F-8B9A-80058CAEF4D7Q54947604-60D3997C-E106-4827-901C-F10C38C0A5BFQ54953784-CE3544A2-3A5E-47E7-AE9F-D7B9701182A8Q54953816-8BEEF78E-92B4-4E29-85ED-E743985275F5Q54953937-D3F3B538-EA88-474B-B47D-FE0D9E6CE56EQ54954013-029F94D1-8627-42E8-8DEE-C8705CD2E484Q54954059-19BD768E-E04F-4424-A63E-8CD1667A70EEQ54954130-28D0A5ED-B5F4-4FAA-AC97-A11E1C019482Q54954136-240ED978-073B-426A-9588-E22DBEAB5BD7Q54954280-6DD4F545-FB64-4B7D-AC55-179C645E305FQ54973868-99182B27-918A-458B-9A09-AB9B332318A7
P1343
Q24627306-E73CB7F8-047F-41D9-9D31-2712259514A1Q24631438-4FBAA190-39A3-4FAC-8620-A05EEC5E6996Q24791830-F8CDB370-7514-4ED6-8068-CE2608BCF2E6Q27022355-A778E342-55A0-4F97-86BC-0C0BF20CBD55Q27348507-CCC852E5-4F4E-4282-B696-CE0FC24D805EQ30429380-1480FD29-17F2-497F-9F0F-B10C6767C30AQ30487052-9B4C0AAF-F7E4-4716-990F-DDB9CDFA1916Q30875021-7AD3A530-3DF3-446B-8E8D-D67093BD9530Q33399049-82436919-EA4A-4EA7-A73B-6E184B8FADB8Q33559683-4F556FE5-4423-4706-93F7-E0E35F23CF43Q33726956-276822CA-B3C2-4794-9682-3A233D4D43A7Q33755862-A647060F-B5DF-49ED-9948-B511EDF2267AQ33834171-4BA1C5F7-9CFA-46B7-91EC-9C1D436AF6FFQ33918101-B5877478-4174-434E-9C98-52184BF3E265Q33978378-7D3D715D-240F-439E-A274-E2BE1CC57ABDQ34253185-A9C53A53-FE54-4026-AE13-0E9F7EC7C90FQ34338564-C4185749-9F21-407A-8CE8-2A073C6F2C51Q34365708-806C4EFA-58BB-4D3C-BAFB-0F2335B8BE85Q34383962-860EA9AB-1A80-45F3-A0ED-ECFDB0DA5D5EQ34540273-2474B2D2-FC81-4EF7-9E04-485A616BA929Q34639532-2846132D-C0E4-4F2B-8656-E32961FFC2CAQ34761941-AF1B0405-144A-48C5-8A48-3FC806F1B05CQ34986178-87978AEB-649A-433B-93A8-5A93DC5F7264Q34986188-43F17EF2-8034-47DB-A6F8-E0825CEF0936Q34996130-F8DA2D09-BCFB-46AD-8F68-29EB72018D1AQ35722779-5692FB1D-D50F-4DDA-8EE4-B9D6B156565CQ35959897-3949CF47-4341-49F1-8CB5-0460083E8B4EQ36506366-2407F489-454D-4E40-BCE9-98C435659966Q36563659-47A2B6CB-F35F-4073-B8F9-CB4E8C72010FQ36590195-FAD58F3F-88C2-41A3-919C-47C69C85E668Q36646490-C4A3CF82-C867-4867-872E-F9539D50E13AQ36944185-EF4BA9EF-9429-4F77-BA27-AA7D94F7A5A1Q36982042-2ECCC9FF-8B7D-418C-9C19-5AF30D74716DQ36990701-60AE9705-5785-4C3C-BE78-9788200E26D1Q37034487-2AD364BA-B795-4F1A-AA68-66DE7FE8A429Q37165194-4D7C416D-979C-4645-A914-BCD81FC7B0C9Q37211362-3F6104AB-2B36-467C-B233-3BA4223CA134Q37454384-96F94AFC-3A08-4888-9D3E-AA4F6EBEBCE2Q37480713-29908863-7988-42C0-B1F3-6260724C89A9Q37506648-0593050B-EC43-4D4B-B06D-440328BB640A
P2860
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
@en
type
label
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
@en
prefLabel
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
@en
P2093
P4510
P1433
P1476
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines
@en
P2093
P304
P407
P577
2000-04-01T00:00:00Z